Form 8-K - Current report:
SEC Accession No. 0001683168-25-004759
Filing Date
2025-06-26
Accepted
2025-06-25 20:46:08
Documents
14
Period of Report
2025-06-25
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT phio_8k.htm   iXBRL 8-K 30583
2 PRESS RELEASE, DATED JUNE 25, 2025 phio_ex9901.htm EX-99.1 13452
6 GRAPHIC image_002.jpg GRAPHIC 2698
  Complete submission text file 0001683168-25-004759.txt   217863

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE phio-20250625.xsd EX-101.SCH 3020
4 XBRL LABEL FILE phio-20250625_lab.xml EX-101.LAB 34239
5 XBRL PRESENTATION FILE phio-20250625_pre.xml EX-101.PRE 22362
16 EXTRACTED XBRL INSTANCE DOCUMENT phio_8k_htm.xml XML 3700
Mailing Address 411 SWEDELAND ROAD SUITE 23-1080 KING OF PRUSSIA PA 19406
Business Address 411 SWEDELAND ROAD SUITE 23-1080 KING OF PRUSSIA PA 19406 (508) 767-3861
Phio Pharmaceuticals Corp. (Filer) CIK: 0001533040 (see all company filings)

EIN.: 453215903 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36304 | Film No.: 251074855
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)